Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous nesiritide in acute heart failure.

Mark A Knox1, Timothy Dancy, William Mook

  • 1Department of Family Medicine, University of Pittsburgh Medical Center Presbyterian Shadyside, Pittsburgh, Pennsylvania 15232, USA. knoxma@upmc.edu

American Journal of Therapeutics
|May 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid nodules.

American family physician·2013
Same author

Should we screen patients for Barrett's esophagus? No: the case against screening.

American family physician·2011
Same author

Optimize your use of stress tests: a Q&A guide.

The Journal of family practice·2010
Same author

Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery.

Transfusion·2006
Same author

Nanomechanics: a new picture of plasticity.

Nature materials·2005
Same author

The acromioclavicular joint.

Primary care·2004

Nesiritide did not improve hospital stay or readmission rates for congestive heart failure (CHF) patients. However, nesiritide significantly increased healthcare charges, particularly for patients with higher ejection fractions.

Area of Science:

  • Cardiology
  • Pharmacoeconomics
  • Health Services Research

Background:

  • Congestive heart failure (CHF) is a significant cause of hospitalization and healthcare expenditure.
  • Nesiritide is a natriuretic peptide used in managing acute decompensated CHF.
  • Understanding the economic and clinical impact of nesiritide is crucial for treatment guidelines.

Purpose of the Study:

  • To evaluate the comparative effectiveness of nesiritide versus usual care in patients with decompensated CHF.
  • To assess the impact of nesiritide on length of hospital stay, readmission rates, and associated healthcare charges.

Main Methods:

  • A structured retrospective chart review of 127 patients admitted with decompensated CHF.
  • Data collected included initial length of stay, 3-month readmission rates, 3-month mortality, and pharmacy/hospital charges.

Related Experiment Videos

  • Analysis stratified by ejection fraction (>30% vs. <=30%).

    • Main Results:

    • Nesiritide showed no significant effect on initial length of stay, readmission rates, or 3-month mortality.
    • Patients with ejection fraction >30% experienced longer hospital stays with nesiritide.
    • Nesiritide treatment resulted in significantly higher pharmacy and hospital charges.

    Conclusions:

    • Nesiritide does not improve key clinical outcomes like length of stay, readmissions, or mortality in CHF patients.
    • The use of nesiritide is associated with substantially increased healthcare costs.
    • Further pharmacoeconomic analyses are needed to guide nesiritide's role in CHF management.